| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1365-2265.2003.01753.X |
| P698 | PubMed publication ID | 12699437 |
| P50 | author | Louis Gooren | Q6687277 |
| Erik J. Giltay | Q37830332 | ||
| P2093 | author name string | Henk Asscheman | |
| Tom Teerlink | |||
| Jacob C Seidell | |||
| Peter G Scheffer | |||
| Jolanda M H Elbers | |||
| P2860 | cites work | Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group | Q29615228 |
| Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias | Q29616292 | ||
| Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland | Q33854508 | ||
| Androgen replacement therapy in the aging male--a critical evaluation | Q34277156 | ||
| Clinical practice. Postmenopausal hormone-replacement therapy | Q34300254 | ||
| An immunochemical method for the selective measurement of two triglyceride lipases in human postheparin plasma | Q40341530 | ||
| Obesity, lipids, cardiovascular risk, and androgen excess | Q40572164 | ||
| The relationship of natural androgens to coronary heart disease in males: a review | Q41131386 | ||
| Women have a larger and less atherogenic low density lipoprotein particle size than men. | Q47338349 | ||
| Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism | Q48002594 | ||
| Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. | Q50119393 | ||
| Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. | Q50991440 | ||
| Insulin resistance, secretion, and metabolism in users of oral contraceptives | Q54279369 | ||
| Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue? | Q55065776 | ||
| Body fat distribution and male/female differences in lipids and lipoproteins | Q57540670 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | insulin resistance | Q1053470 |
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 562-571 | |
| P577 | publication date | 2003-05-01 | |
| P1433 | published in | Clinical Endocrinology | Q15762781 |
| P1476 | title | Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects | |
| P478 | volume | 58 |
| Q34474654 | A review of the physical and metabolic effects of cross-sex hormonal therapy in the treatment of gender dysphoria |
| Q38900046 | Advances in the Care of Transgender Children and Adolescents |
| Q34034792 | Alterations in Lipids and Adipocyte Hormones in Female-to-Male Transsexuals |
| Q37061868 | Androgens and insulin--two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. |
| Q51037378 | Androgens modulate osteocalcin release by human visceral adipose tissue. |
| Q54569521 | Androgens, body fat Distribution and Adipogenesis. |
| Q59485355 | Cardiovascular health in transgender people |
| Q46461813 | Central adiposity and decreased heart rate variability in postmenopause: a cross-sectional study. |
| Q50583375 | Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome. |
| Q33575421 | Complementary therapy in polycystic ovary syndrome |
| Q38268810 | Cross-sex hormone therapy for gender dysphoria. |
| Q40602937 | Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis. |
| Q33987184 | Dietary calcium intake is associated with less gain in intra-abdominal adipose tissue over 1 year |
| Q36201486 | Do changes in sex steroid hormones precede or follow increases in body weight during the menopause transition? Results from the Study of Women's Health Across the Nation |
| Q90380755 | Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review |
| Q33923490 | Estradiol Binds to Insulin and Insulin Receptor Decreasing Insulin Binding in vitro |
| Q34047348 | Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys |
| Q90602482 | Gender and Sex Differences in Adipose Tissue |
| Q38092017 | Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension |
| Q34132096 | Gynaecological aspects of the treatment and follow-up of transsexual men and women |
| Q90087822 | Health considerations for transgender women and remaining unknowns: a narrative review |
| Q37667452 | Injustice to transsexual women in a hetero-normative healthcare system |
| Q33569169 | Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications |
| Q55379893 | Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women. |
| Q80193527 | Low testosterone levels are associated with coronary artery disease in male patients with angina |
| Q33904576 | MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. |
| Q34258902 | Medical management of adult transsexual persons |
| Q38107528 | Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects |
| Q37494304 | Metabolic syndrome and polycystic ovary syndrome... and vice versa |
| Q37068841 | Metabolic syndrome and reproduction: I. testicular function. |
| Q54232638 | NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk? |
| Q44402842 | No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours |
| Q82419051 | Obesity and polycystic ovary syndrome |
| Q37734592 | Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20-38 years in China |
| Q38787403 | Oestrogen and anti-androgen therapy for transgender women. |
| Q98163759 | Pathophysiological effects of androgens on the female vascular system |
| Q38673882 | Pharmacotherapy Considerations in the Management of Transgender Patients: A Brief Review |
| Q37071255 | Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications |
| Q37585306 | Polycystic ovary syndrome, obesity and reproductive implications |
| Q37173546 | Polycystic ovary syndrome: effect and mechanisms of acupuncture for ovulation induction |
| Q30359711 | Priorities for transgender medical and healthcare research. |
| Q34660226 | Safety of Physiological Testosterone Therapy in Women: Lessons from Female-to-Male Transsexuals (FMT) Treated with Pharmacological Testosterone Therapy |
| Q45270989 | Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters |
| Q36568204 | Serum under-carboxylated osteocalcin levels in women with polycystic ovary syndrome: weight-dependent relationships with endocrine and metabolic traits |
| Q64294650 | Sex Hormone Levels - Estradiol, Testosterone, and Sex Hormone Binding Globulin as a Risk Marker for Atherosclerotic Coronary Artery Disease in Post-menopausal Women |
| Q56706472 | Sex and gender: what is the difference? |
| Q34758488 | Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. |
| Q35757562 | Sex hormones, insulin sensitivity, and diabetes mellitus |
| Q60960879 | Sex hormones, obesity and type 2 diabetes: is there a link? |
| Q51661057 | Sympathovagal imbalance in transsexual subjects. |
| Q35849393 | Testosterone increases the muscle protein synthesis rate but does not affect very-low-density lipoprotein metabolism in obese premenopausal women. |
| Q38809734 | Testosterone therapy for transgender men. |
| Q37678925 | Testosterone, SHBG and cardiovascular health in postmenopausal women. |
| Q45106114 | The M16 mouse: an outbred animal model of early onset polygenic obesity and diabesity |
| Q47567144 | The Role of Androgen Excess in Metabolic Dysfunction in Women : Androgen Excess and Female Metabolic Dysfunction |
| Q37869374 | The paradox of low BNP levels in obesity |
| Q38007199 | The safety of postmenopausal testosterone therapy |
| Q26828981 | The striking similarities in the metabolic associations of female androgen excess and male androgen deficiency |
Search more.